Results 221 to 230 of about 11,815 (249)
Some of the next articles are maybe not open access.
Australian family physician, 2018
Hyponatraemia is one of the most commonly encountered electrolyte abnormalities in general practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an important but under-recognised cause.This article explores the presentation, investigation, diagnosis and management of SIADH.SIADH can occur secondary to medications, malignancy ...
Kristen, Tee, Jerry, Dang
openaire +1 more source
Hyponatraemia is one of the most commonly encountered electrolyte abnormalities in general practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an important but under-recognised cause.This article explores the presentation, investigation, diagnosis and management of SIADH.SIADH can occur secondary to medications, malignancy ...
Kristen, Tee, Jerry, Dang
openaire +1 more source
2015
Das Syndrom der inappropriaten („inadaquaten“) Sekretion von AntidiuretischemHormon (SIADH) kann man allgemein als eine Storung der Osmoregulation definieren, die mit einer Wasserintoleranz einhergeht und zu einer euvolamen Hyponatriamie f€uhrt. Ursachlich ist eine relativ (in Bezug auf die aktuelle Natriumkonzentration i.S.) vermehrte Sekretion von ...
openaire +1 more source
Das Syndrom der inappropriaten („inadaquaten“) Sekretion von AntidiuretischemHormon (SIADH) kann man allgemein als eine Storung der Osmoregulation definieren, die mit einer Wasserintoleranz einhergeht und zu einer euvolamen Hyponatriamie f€uhrt. Ursachlich ist eine relativ (in Bezug auf die aktuelle Natriumkonzentration i.S.) vermehrte Sekretion von ...
openaire +1 more source
Wallenberg Syndrome with SIADH
European Neurology, 2004Nobuatsu, Nomoto +4 more
openaire +2 more sources
Annales d'endocrinologie, 2012
The vaptans are non-peptide arginine-vasopressin-receptor antagonists, that are orally and intravenously active. A few vaptans have undergone sufficient clinical development to be on the market. In the EU only tolvaptan is accepted to treat hyponatremia related to SIADH. The place of this new treatment is compared with water restriction, demeclocyclin,
openaire +1 more source
The vaptans are non-peptide arginine-vasopressin-receptor antagonists, that are orally and intravenously active. A few vaptans have undergone sufficient clinical development to be on the market. In the EU only tolvaptan is accepted to treat hyponatremia related to SIADH. The place of this new treatment is compared with water restriction, demeclocyclin,
openaire +1 more source